Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.79 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.68 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155746 | 1.00 | LTA4H (0.79) | LTA4HCHRNB4CHRNA3 | |
| SCHEMBL5332805 | 1.00 | LTA4H (0.79) | LTA4HCHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL9237449 | 0.98 | LTA4H (0.77) | LTA4HCHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL4742124 | 0.98 | LTA4H (0.77) | LTA4HCHRNB4CHRNA3 | |
| SCHEMBL3166997 | 0.95 | LTA4H (0.88) | LTA4H | |
| SCHEMBL4317030 | 0.94 | LTA4H (0.91) | LTA4H | |
| SCHEMBL14544796 | 0.94 | LTA4H (0.91) | LTA4H | |
| SCHEMBL4317023 | 0.94 | LTA4H (0.91) | LTA4H | |
| SCHEMBL10326529 | 0.90 | LTA4H (0.84) | LTA4H | |
| SCHEMBL10326840 | 0.90 | LTA4H (0.84) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Redona Therapeutics, Inc. | 2024-08-01 | — | — | US | disclosed |
| CN-116157392-A | Compounds targeting RNA binding proteins or RNA modification proteins | 雷多纳治疗公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-4114831-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Twentyeight-Seven, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-107667097-B | Separation of enantiomers of 3-ethylbicyclo [3.2.0] hept-3-en-6-one | 诺瓦色生物公司 | 2021-02-12 | — | — | CN | disclosed |
| EP-3303308-B1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | NOVASSAY SA (CH) | 2019-10-09 | — | — | EP | disclosed |
| US-10150723-B2 | Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one | NOVASSAY S.A. (CH) | 2018-12-11 | — | — | US | disclosed |
| EP-2792664-B1 | OPTICAL RESOLUTION METHOD FOR BICYCLIC COMPOUND USING ASYMMETRIC CATALYST | DAIICHI SANKYO CO LTD (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-20180134643-A1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | NOVASSAY S.A. (CH) | 2018-05-17 | — | — | US | disclosed |
| EP-3303308-A1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | Novassay SA (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016146299-A1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | NOVASSAY SA (CH) | 2016-09-22 | — | — | WO | disclosed |
| EP-2792664-A1 | OPTICAL RESOLUTION METHOD FOR BICYCLIC COMPOUND USING ASYMMETRIC CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-22 | — | — | EP | disclosed |
| EP-2792664-A1 | OPTICAL RESOLUTION METHOD FOR BICYCLIC COMPOUND USING ASYMMETRIC CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-20140296569-A1 | Optical Resolution Method for Bicyclic Compound Using Asymmetric Catalyst | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296569-A1 | Optical Resolution Method for Bicyclic Compound Using Asymmetric Catalyst | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296569-A1 | Optical Resolution Method for Bicyclic Compound Using Asymmetric Catalyst | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| WO-2010083870-A1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296569-A1 | Optical Resolution Method for Bicyclic Compound Using Asymmetric Catalyst | OXER1, OCIAD2, AOC2 | LTA4H 1738/4885CHRNB4 2928/4885CHRNA3 2198/4885 |
| US-20180134643-A1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | ALDH7A1, OPRK1, SCN3A | LTA4H 1321/4885CHRNB4 520/4885CHRNA3 95/4885 |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | METAP2, METAP1, XPNPEP2 | LTA4H 1135/4885CHRNB4 4849/4885CHRNA3 4806/4885 |
| US-10150723-B2 | Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one | ALDH7A1, OPRK1, SCN3A | LTA4H 1321/4885CHRNB4 520/4885CHRNA3 95/4885 |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | NSUN3, NSUN2, RBM3 | LTA4H 4601/4885CHRNB4 4780/4885CHRNA3 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.